Publications by authors named "Pam R Tsuruda"
J Inflamm (Lond)
December 2017
Article Synopsis
- Tofacitinib, a JAK inhibitor, shows potential in treating IBD by effectively reducing intestinal inflammation without significant systemic immunosuppression.
- In a mouse model, both oral and intracecal administration of tofacitinib improved colitis symptoms, with intracecal dosing achieving better localized drug effects.
- This approach may allow for targeted treatment of intestinal inflammation, separating local benefits from general immune system suppression, which is a major concern with current systemic therapies.
